Front Row Advisors’s Trueblue TBI Stock Holding History

Front Row Advisors’s Portfolio TBI Stock Details TBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-84	Closed	-$1K	–	1012
2020 Q2	$1K	Hold	84	–	–	﹤0.01%	952
2020 Q1	$1K	Buy	+84	New	+$1.5K	﹤0.01%	928

Other funds holding TBI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Pzena Investment Management New York $34.1B AUM 23.81% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Front Row Advisors's TBI Position: Q3 2020 in Review

Front Row Advisors sold out of Trueblue (TBI) in Q3 2020, closing a stake of 84 shares — an estimated $1K sold.

Front Row Advisors first reported a position in TBI in Q1 2020 and held it in 2 quarters. The position peaked at $1K in Q2 2020. 158 funds tracked by Wall St. Rank hold TBI as of Q3 2020.

Front Row Advisors reported no remaining Trueblue position as of Q3 2020 after selling out during the quarter.
Front Row Advisors sold 84 Trueblue shares in Q3 2020, an estimated $1K.
Front Row Advisors first reported a position in Trueblue in Q1 2020 and held it in 2 quarters.
Front Row Advisors's Trueblue position peaked at $1K in Q2 2020.
158 funds tracked by Wall St. Rank held Trueblue as of Q3 2020.

Based on Front Row Advisors's 13F filing for Q3 2020, filed 30 Nov 2020.